rare disease

Diseases that affect few patients, often genetic, and drugs for them.

Theme · 4 companies · 0 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ASPE Aspen Neuroscience, Inc.

    In development“Our lead microglia program initially targets pediatric leukodystrophies, a group of rare, genetically defined neurological disorders that primarily affect the white matter of the CNS.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • ETRA Electra Therapeutics, Inc.

    In development“HLH is a rare, life-threatening hyperinflammatory disease characterized by immune dysregulation leading to excessive cytokine release and rapid progression to multiorgan dysfunction.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • PFE Pfizer

    Sells it“Rare disease product portfolio for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases – select products include: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • TWST Twist Bioscience

    Supplies it“Our customers use our NGS products in research and in the development and commercialization of their own workflows, including cancer detection through liquid biopsy and MRD as well as rare disease.”

    Latest 10-KFY2026Positive ·

    AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.

    • Revenue$459.4MYoY +22.0%
    • Net income−$130.2MYoY −67.6%

Feedback